How Wegovy Works: Semaglutide Weight Loss Injection Explained

Wegovy is changing how doctors treat obesity in the United States by offering a once-weekly semaglutide injection approved by the FDA for chronic weight management in certain adults with obesity or overweight and related health conditions FDA, 06/04/2021.

As of: 06/08/2026 | Reading time: approx. 8 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

What Wegovy Is and How It Works

Wegovy is a brand-name injection containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist designed specifically for chronic weight management in adults who meet defined body mass index and comorbidity criteria FDA, 06/04/2021.

The medication is administered as a once-weekly subcutaneous injection using a prefilled pen that patients or caregivers can typically use at home after appropriate training from a healthcare professional Novo Nordisk, 05/15/2024.

Semaglutide in Wegovy mimics human GLP-1, a hormone involved in appetite regulation and glucose control, helping patients feel fuller and reducing appetite when used together with a reduced-calorie diet and increased physical activity New England Journal of Medicine, 03/18/2021.

Why Wegovy Matters for US Consumers and Industry

In the United States, Wegovy is used for adults with a body mass index of at least 30 kg/m2 or at least 27 kg/m2 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia, when combined with lifestyle changes FDA, 06/04/2021.

The STEP clinical trial program found that adults with obesity who used once-weekly semaglutide alongside diet and exercise achieved significantly greater weight reduction over 68 weeks compared with placebo plus lifestyle changes New England Journal of Medicine, 03/18/2021.

US obesity specialists and primary care providers increasingly consider GLP-1 based therapies such as Wegovy as part of long-term obesity management strategies for appropriate patients, alongside behavioral and nutritional counseling CDC, 02/28/2024.

Wegovy in the US and Global Market

Wegovy is available in the United States only by prescription, and prescribers must evaluate each patient for eligibility, medical history, and potential risks before starting therapy Novo Nordisk, 05/15/2024.

Novo Nordisk has reported strong global demand for semaglutide-based obesity treatments and has been increasing manufacturing capacity to improve supply reliability while coordinating launches in additional markets Novo Nordisk, 02/01/2024.

In the United States, Wegovy competes in a growing anti-obesity drug market that also includes other GLP-1 receptor agonists indicated for weight management, reflecting broader industry investment in medical obesity treatment Financial Times, 01/10/2024.

• Prescription GLP-1 injection for chronic weight management
• Used alongside reduced-calorie diet and increased physical activity
• Intended for adults meeting defined BMI and comorbidity criteria
• Once-weekly dosing via prefilled injection pen
• Available by prescription in the United States

Frequently Asked Questions About Wegovy

Who is Wegovy for in the United States?
Wegovy is indicated for adults with obesity or overweight plus at least one weight-related condition, as an adjunct to reduced-calorie diet and increased physical activity FDA, 06/04/2021.

Is Wegovy the same as semaglutide for diabetes?
Wegovy and some diabetes medications both contain semaglutide but are approved for different indications, dosing, and target populations, so patients should only use products as prescribed for their specific condition FDA, 01/11/2024.

Is there an oral Wegovy pill available?
As of early 2026, Wegovy is available as an injectable formulation, while an oral semaglutide pill for obesity is being studied separately and is not the same product as the injection used for weight management Novo Nordisk, 03/06/2024.

Novo Nordisk, the company behind Wegovy, develops a range of therapies focused on diabetes, obesity, and other serious chronic diseases and distributes Wegovy in the United States through prescription channels.

Novo Nordisk A/S is listed on the stock market, and the issuer associated with Wegovy has the ISIN DK0060534915 for reference in financial contexts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.